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R E S E A R C H  L E T T E R
An FCER2 polymorphism is associated with increased 
oral leukotriene receptor antagonists and allergic rhinitis 
prescribing
The Fc Fragment of IgE Receptor II (FCER2) is expressed in several 
cells, such as macrophages, eosinophils, B cells and platelets. Studies 
have suggested that FCER2 is involved in the regulation of IgE re-
sponses, growth and differentiation of T and B cells, cellular adher-
ence and antigen presentation.1,2 The activation of the receptor 
results in down- regulation of IgE- mediated immune responses.2 Two 
studies found that individuals with asthma on inhaled corticoster-
oids (ICS) with the CC genotype of the rs28364072 polymorphism 
had a two- fold increased odds of asthma exacerbations and uncon-
trolled asthma compared with individuals with at least one copy of 
the T allele (CT/TT).2,3 While the literature suggests an association 
between this FCER2 polymorphism and asthma exacerbations while 
on ICS, it is unclear whether the CC genotype of the rs28364072 
polymorphism translates into different prescribing patterns. Thus, 
we explored the association between the FCER2 polymorphism and 
increased prescribing of medication for eczema, asthma, and allergic 
rhinitis, over a decade.
We used the BREATHE dataset, a cross- sectional study of possi-
ble gene- environment interactions in 1100 children and adults with 
physician- diagnosed asthma, aged between 2 and 22 years, linked 
with the Community Pharmacy database. The outcomes considered 
were the annual number of asthma- , eczema- , and allergic rhinitis– 
related prescriptions. We used generalised linear mixed models with 
a negative binomial family and a random effect for the participant, 
adjusted for age, gender and the FCER2 polymorphism. All analy-
ses were performed on children and young adults with a physician 
diagnosis or self- report of the disease, except rhinitis. We decided 
to perform rhinitis- related analysis in the entire sample due to dis-
crepant reporting in the data and add a sensitivity analysis, analys-
ing only children and young adults that reported having rhinitis (see 
Supplementary Material for more details on the methodology).
Of the 1100 children and young adults in the dataset, 139 (12.6%) 
individuals did not have information about the FCER2 polymorphism 
and were excluded from the analysis. Thirty- four individuals (3.1%) 
were excluded due to missing clinical information. The final dataset 
included 927 children and adults with asthma.
The CC genotype was present in 76 (8.2%) of the participants, 
the TC genotype in 344 (37.1%) and the TT genotype in 507 (54.7%). 
Table 1 presents the characteristics of the sample at baseline. Most 
children and young adults were male (60%) and had a mean age of 
10 years (standard deviation = 4.2). Of the 927 participants included 
in the study, 493 (53.2%) reported having eczema, 397 (42.8%) re-
ported having rhinitis, 230 (24.8%) reported having rhinitis and ec-
zema, and 267 (28.8%) reported having neither eczema nor rhinitis.
Regarding dispensed asthma- related prescriptions, almost all 
participants (97.2%) had at least one short- acting β2- agonists (SABA) 
prescription dispensed over the period studied, followed by 79.6% 
of participants who were dispensed at least one prescription for ICS. 
Almost half of the participants (45.6%) were dispensed one or more 
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TA B L E  1  Characteristics of the sample at baseline (2005)
TT/TC 




Male 508 (59.7%) 48 (63.2%) 556 (60%)
Female 341 (40.3%) 28 (36.8%) 371 (40%)
Age group
Mean (Min– Max) 10.4 (1– 22) 9.8 (3– 21) 10.3 (1– 22)
Standard deviation 4.2 4.2 4.2
Self- report of eczema
No 397 (46.6%) 37 (48.7%) 434 (46.8%)
Yes 454 (53.4%) 39 (51.3%) 493 (53.2%)
Self- report of allergic rhinitis
No 484 (56.9%) 46 (60.5%) 530 (57.2%)
Yes 367 (43.1%) 30 (39.5%) 397 (42.8%)
Self- report of eczema and allergic rhinitis
None 242 (28.4%) 25 (32.9%) 267 (28.8%)
Only eczema 242 (28.4%) 21 (27.6%) 263 (28.4%)
Only allergic rhinitis 155 (18.2%) 12 (15.8%) 167 (18%)
Both 212 (25%) 18 (23.7%) 230 (24.8%)
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prescriptions for a combination of long- acting β2- agonists (LABA) 
and ICS, and 30.8% of participants were dispensed at least one pre-
scription of oral leukotriene receptor antagonists (LTRA). Despite 
recommendations against the use of LABA alone,4 53 children and 
young adults (5.7%) were dispensed at least one LABA prescription 
without concomitant ICS over a decade.
Children and adults with the CC genotype were associated with 
a higher number of dispensed prescriptions of LTRA than those with 
the TT or TC genotype (IRR: 3.86, 95% CI: 1.41– 10.59) (Table 2). The 
use of LTRA differs according to the age of the patient. Thus, we 
restricted the analysis to children aged under seven years to observe 
the differences according to the FCER2 polymorphism in this age 
range. The proportion of children who were dispensed at least one 
LTRA prescription decreased to 22.6% (vs.30.8% total sample). The 
mean number of LTRA prescriptions dispensed to children under 
seven years with the CC genotype was 3.2 and with the TT or TC 
genotype was 2.06 over a decade.
No association was found between the FCER2 polymorphism 
and the number of nasal corticosteroid prescriptions dispensed (IRR: 
1.81, 95% CI: 0.96– 3.41), although a weak- to- moderate associa-
tion was found for all allergic rhinitis prescriptions (IRR: 1.88, 95% 
CI: 1.00, 3.52) (Table 2). The sensitivity analysis showed the associ-
ation was no longer statistically significant (IRR: 1.82, 95% CI: 0.76, 
4.31) (Table S4).
There was no evidence of an association between the FCER2 
polymorphism and the number of prescriptions dispensed for reliev-
ers, ICS, a combination of LABA and ICS, oral antihistamines, and 
eczema- related prescriptions (Table 2).
This research demonstrates that children and adults with the CC 
genotype, for the rs28364072 polymorphism of the FCER2 gene, 
were dispensed more prescriptions for oral LTRA and allergic rhini-
tis, over more than a decade, than children and adults with the TT 
or TC genotype.
The exact role of the FCER2 gene in IgE regulation is still un-
known. FCER2 expression has been shown to be induced specifically 
by interleukin 4 (IL- 4).5 Corticosteroids inhibit the transcription of 
IL- 4, which could be one of the reasons for their efficacy in chronic 
allergic inflammation.6 However, some studies have found that cor-
ticosteroids may be less effective in the presence of elevated levels 
of IgE and IL- 4. Wu et al.7 found that the use of glucocorticoids was 
associated with increased IgE levels in the presence of in vivo IL- 4. 
Another study found that the increase in IgE levels concerning glu-
cocorticoid administration was only present in atopic asthmatic pa-
tients and not in non- atopic patients.8
Variations in disease severity in conditions such as asthma may 
influence prescribing. People with more severe disease will often 
have more long- term medication, such as LABA, LTRA and oral ste-
roids. However, we did not find an association between FCER2 and 
a higher number of dispensed prescriptions for SABA, ICS or OCS. 
We only found an association between FCER2 and a higher num-
ber of LTRA prescriptions, which raises the possibility that the need 
Key Messages
• We explored associations between genotype and pre-
scriptions for allergic conditions in the BREATHE cohort.
• The low- affinity IgE receptor CC genotype was associ-
ated with increased prescriptions for allergic conditions.
• Associations were not all statistically significant, and 
these findings need replication in another cohort study.
TA B L E  2  Association between the FCER2 polymorphism and 





All asthma- related prescriptionsa 
TT/TC vs. CC 1.33 (1.02, 1.75)
Reliever prescriptionsa 
TT/TC vs. CC 1.25 (0.97, 1.60)
Inhaled corticosteroid prescriptionsa 
TT/TC vs. CC 1.20 (0.84, 1.73)
Long- acting β2- agonist with corticosteroid prescriptions
a 
TT/TC vs. CC 1.70 (0.69, 4.19)
Leukotriene prescriptionsa 
TT/TC vs. CC 3.86 (1.41, 10.59)
Oral corticosteroid prescriptionsa 
TT/TC vs. CC 1.44 (0.90, 2.29)
Oral antihistamines prescriptionsa 
TT/TC vs. CC 0.89 (0.54, 1.47)
All allergic rhinitis prescriptionsa 
TT/TC vs.CC 1.88 (1.00, 3.52)
Nasal corticosteroid prescriptionsa 
TT/TC vs. CC 1.81 (0.96, 3.41)
All eczema- related prescriptionsb 
TT/TC vs. CC 1.71 (0.91, 3.20)
Emollient prescriptionsb 
TT/TC vs. CC 1.85 (0.90, 3.79)
Topical corticosteroid prescriptionsb 
TT/TC vs. CC 1.54 (0.86, 2.78)
Prescriptions for mild eczemab 
TT/TC vs. CC 1.66 (0.88, 3.13)
Prescriptions for moderate eczemab 
TT/TC vs. CC 1.72 (0.87, 3.39)
Prescriptions for severe eczemab 
TT/TC vs. CC 1.44 (0.61, 3.43)
Note: Incidence rate ratios were adjusted for gender and age.
aAnalysis was conducted on all children and young adults with asthma 
(n = 927).
bAnalysis was conducted on children and young adults with asthma and 
eczema (n = 493).
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for long- term prescribing for other medicines for asthma, and other 
chronic diseases, may be influenced by biological mechanisms that 
we may be unable to assess through currently available clinical out-
comes. Importantly, neither the doctor nor the patient was aware of 
the presence of the patients' genotype.
We need to understand the reasons behind the increase in LTRA 
prescribing. Perhaps the increased symptoms in patients with the 
CC genotype, compared to those with the TC or TT genotype, re-
sults from a poorer response to ICS, even in the presence of LABA, 
leading to increased prescribing of LTRAs. GPs might also consider 
prescribing LTRAs for patients with asthma and concomitant allergic 
rhinitis. The patient could be showing a greater response to LTRAs, 
which may be reported to the GPs, and, consequently, the GP pre-
scribes more LTRAs. If that is the case, genetic profiling could allow 
us to proactively define medication needs in patient sub- groups, 
developing better treatment strategies, improving patient quality 
of life, and reducing overprescribing, thus saving costs for national 
health systems.
Our study also has several limitations. Dispensed prescriptions 
provide more information than prescribed prescriptions, as one 
knows that the prescription was dispensed, but it is impossible to 
determine whether the patient followed the doctor's recommen-
dation and used the medicine or whether the medication was not 
used or shared among members of the household. It is also impos-
sible to determine whether the patient bought additional over- the- 
counter medication or alternative medicine. We also considered 
the dispensing of medication as a proxy for severity, consequently 
using the medication, while other studies use self- report of medi-
cation. However, our study also suffers from self- report bias since 
eczema and rhinitis were self- reported by the participants. The 
self- report of rhinitis was inconsistent with rhinitis dispensing, 
which brings more uncertainty regarding the analysis. Although 
the association between allergic rhinitis prescribing and the FCER2 
polymorphism was not statistically significant in children and 
adults who reported having rhinitis, the estimate was similar in 
both analyses. Outcomes should be validated and harmonised to 
improve reproducibility and assessment of asthma severity, and 
guidelines for research using routine healthcare databases should 
be developed.9 Our study also has uncontrolled confounding. It is 
unclear whether other genetic polymorphisms may be influencing 
or contributing to our results. Ideally, one should also have so-
cioeconomic and behavioural factors to control for confounding. 
However, albeit advantageous, this is also a limitation of using 
routine healthcare databases. Furthermore, all participants are 
assumed to be Caucasian, of European ancestry, according to phy-
sicians. However, this information was not recorded and serves 
as a limitation as response to treatment varies between different 
ethnicities. Further studies are needed to replicate our results. 
This is an exploratory study, unrepresentative of the population. 
One should be aware of different behaviours across different 
subgroups regarding medication uptake. Ethnicity, comorbidities, 
such as obesity, and use of healthcare should, in future, be re-
corded to better understand the relationships we observed.
However, more expensive, longitudinal studies should be con-
ducted to understand disease progression and evaluate the long- 
term effects of treatment. Individuals affected by chronic diseases, 
such as eczema and asthma can experience periods when they are 
well- controlled on no medication or preventive medicine alone. 
However, at any time, symptoms can reappear, and more intensive 
treatment may again be necessary. Hence, conducting longitudinal 
studies compared with cross- sectional studies is critical.
A better understanding of the role of genetic biomarkers on pa-
tient prescribing might help us improve patients’ quality of life with 
chronic illnesses. The information from these studies may help de-
velop targeted therapies for these patients and lead to improved 
asthma- related clinical outcomes, such as asthma control and quality 
of life.
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